Acadia presented to Goldman Sach Bio conference this morning. Link to presentation is on the Acadia website under investors/media. Around the 37.30 minute mark he talks about the phase 3 trial restart being "very near". It will be staged, but again he confirmed that the results will be coming next year. Very positive around the restart and good to hear no further drag re results into 2022.
Ann: Neuren to capture substantially greater value after Phase 3, page-95
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.88 |
Change
-0.220(1.68%) |
Mkt cap ! $1.607B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.88 | $2.737M | 208.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 767 | $12.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.89 | 1387 | 7 |
View Market Depth
| Last trade - 13.31pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |